Understanding how antigen location and density affect immune cell development
Official title: Potent Signal 1 as a noncanonical Signal 3: antigen location, and peptide:MHCII complex density and half-life as drivers of CD4+ T cell differentiation
Funded at Children's Hosp of Philadelphia · NIH-11033605 · Data updated 2026-11-12
This study looks at how the way immune cells show certain signals affects the development of important immune cells called CD4+ T cells, which help our body fight off diseases like cancer and autoimmune disorders, with the goal of finding better treatments.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Children's Hosp of Philadelphia NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | November 21, 2024 |
| Project end | October 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $267,000 |
| NIH project number | 1R21AI182619-01A1 |
| Project ID | NIH-11033605 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with cancer or autoimmune diseases who may benefit from enhanced immune therapies.
✕Less likely to help
Patients with conditions unrelated to immune response or those not eligible for immunotherapy may not receive benefits from this research.
What this research studies
This research investigates how the location and density of antigens presented by immune cells influence the differentiation of CD4+ T cells, which are crucial for adaptive immune responses. The study aims to explore the roles of different signals that drive T cell activation and differentiation, particularly focusing on the strength of the antigen signal and its interaction with co-stimulatory signals. By examining these mechanisms, the research seeks to improve our understanding of immune responses in both cancer and autoimmune diseases, potentially leading to better therapeutic strategies.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapies for cancer and improved treatments for autoimmune conditions.
How similar studies have gone: Previous research has shown promising results in understanding T cell differentiation through similar mechanisms, indicating potential for success in this area.
Where this research is happening
-
Children's Hosp of Philadelphia
Philadelphia, United States Active
Researchers
- Principal investigator: Eisenlohr, Laurence Crane — Children's Hosp of Philadelphia
- Study coordinator: Eisenlohr, Laurence Crane
Related research
Other NIH-funded projects on the same topics.
-
Emotional and biobehavioral links in parent-infant closeness
A program to understand how parent and baby feel and react to each other in early life, with the goal of guiding better child social and emotional development.
-
Leukodystrophy Clinical Careers and Mentorship Network
A program to train, mentor, and support clinicians and researchers to advance care for people with leukodystrophies.
-
Role of ATP1A3 mutations in sudden death related to epilepsy
Aims to understand how ATP1A3 gene changes may lead to sudden death in kids with epilepsy and is exploring new ways to prevent it.
-
Kids First Data Resource Center: cloud-enabled data sharing for childhood cancer research
A data resource project that makes pediatric cancer data and analyses more accessible to researchers, with the goal of advancing understanding and care for children with cancer.
-
PROMISE: A Network for Real-World Evidence in Rare Pediatric Cancers
A network will collect and harmonize pediatric cancer patient records from multiple centers to create high-quality real-world data that can support quicker, regulatory-ready insights when randomized trials aren’t feasible.
-
Data Hub Core for Down syndrome research
A data hub project is building a big, interoperable platform to securely share and analyze information from people with Down syndrome and related conditions.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.